<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091113</url>
  </required_header>
  <id_info>
    <org_study_id>HAEKA 01-2019</org_study_id>
    <nct_id>NCT04091113</nct_id>
  </id_info>
  <brief_title>Hereditary Angioedema Kininogen Assay</brief_title>
  <acronym>HAEKA</acronym>
  <official_title>Hereditary Angioedema Kininogen Assay: A Multicenter, Epidemiological, Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter epidemiological observational study aiming to explore the cleaved
      high-molecular weight kininogen (cHMWK) including identification and characterization of
      other metabolite/biomarkers in HAE type 1/2 patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hereditary angioedema (HAE) is a rare autosomal dominant genetic disorder characterized by
      recurrent tissue angioedema episodes, mainly caused by mutations in the SERPING1 gene that
      encodes C1 inhibitor (C1-INH), a protease involved in limiting bradykinin production. Low
      levels of C1-INH (HAE type 1) or dysfunctional C1-INH (HAE type 2) lead to bradykinin
      accumulation, resulting in capillary leakage and tissue swelling.

      High Molecular Weight Kininogen (HMWK) proteolysis, by active plasma kallikrein, results in
      bradykinin and cHMWK generation.

      The goal of this study is to explore the cHMWK concentrations in HAE type 1/2 patients, as a
      biomarker for this disease.

      The HAEKA study is performed in collaboration with Shire. Shire is a wholly owned subsidiary
      of Takeda Pharmaceutical Company Limited.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exploring the cleaved high-molecular weight kininogen (cHMWK) as a biomarker in HAE type 1/2 patients, as well as to study the differences between HAE type 1/2 patients without lanadelumab treatment versus patients on lanadelumab treatment.</measure>
    <time_frame>30 months</time_frame>
    <description>Samples from HAE patients without lanadelumab treatment versus patients on lanadelumab treatment will be analyzed for cHMWK via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Studying cHMWK as a biomarker in HAE type 1/2 patients with edema attack, as well as to study the differences between HAE type 1/2 patients without lanadelumab treatment versus patients on lanadelumab treatment.</measure>
    <time_frame>30 months</time_frame>
    <description>Samples from HAE patients without lanadelumab treatment versus patients on lanadelumab treatment collected before/during/after angioedema attacks will be analyzed for cHMWK via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Studying other metabolites as potential biomakers in HAE type 1/2 patients, as well as to study the differences between HAE type 1/2 patients without lanadelumab treatment versus patients on lanadelumab treatment.</measure>
    <time_frame>30 months</time_frame>
    <description>All samples will be analyzed for potential biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>Participants with Hereditary Angioedema</arm_group_label>
    <description>Participants older than 18 years that are clinically diagnosed with Hereditary Angioedema type 1/2 and experienced ≥4 HAE attacks within last 12 month before the enrollment</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hereditary Angioedema type 1/2 patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent is obtained from the participant

          -  The patient with diagnosis of Hereditary Angioedema (HAE) type 1/2 based on
             international guidelines

          -  The patient experienced ≥4 HAE attacks within last 12 month before enrolment in the
             study

          -  The participant is older than 18 years old

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  The patient is not diagnosed with Hereditary Angioedema (HAE) type 1/2

          -  The patient experienced ˂ 4 HAE attacks within last 12 month before enrolment in the
             study

          -  The participant is younger than 18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+49 (0)38180113594</phone>
    <email>volha.skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Toni Förster, PhD</last_name>
    <phone>+49 (0)38180113535</phone>
    <email>toni.foerster@centogene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Magerl, MD</last_name>
      <phone>+49 (0)30450518318</phone>
      <email>markus.magerl@charite.de</email>
    </contact>
    <investigator>
      <last_name>Markus Magerl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang-Goethe-Universität</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emel Aygören-Pürsün, MD</last_name>
      <phone>+49 (0)6963016312</phone>
      <email>aygoeren@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Emel Aygören-Pürsün, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Wedi, MD</last_name>
      <phone>+49 (0)5115327652</phone>
      <email>wedi.bettina@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Bettina Wedi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Hautklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Treudler, MD</last_name>
      <phone>+49 (0)3419718690</phone>
      <email>regina.treudler@uniklinik-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Regina Treudler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hämophilie-Zentrum Rhein Main GmbH</name>
      <address>
        <city>Mörfelden-Walldorf</city>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inmaculada Martinez-Saguer, MD</last_name>
      <phone>+49 6105 9638900</phone>
      <email>inmaculada.martinez@hzrm.de</email>
    </contact>
    <investigator>
      <last_name>Inmaculada Martinez-Saguer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Greve, MD</last_name>
      <phone>+49 (0)73150059501</phone>
      <email>Jens.Greve@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Jens Greve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>Cleaved high-molecular weight kininogen</keyword>
  <keyword>Hereditary Angioedema Type I</keyword>
  <keyword>Hereditary Angioedema Type II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

